AKTX - アカリ・セラピュ―ティクス （Akari Therapeutics Plc） アカリ・セラピュ―ティクスAKTXのチャート
AKTXの企業情報
| symbol | AKTx |
|---|---|
| 会社名 | Akari Therapeutics PLC （アカリ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Akari Therapeutics Plc formerly Celsus Therapeutics Plc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5) including paroxysmal nocturnal hemoglobinuria Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug Coversin a complement inhibitor acts on complement C5 preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases including disease states spanning hematology nephrology transplantation neurology and ophthalmology. アカリ・セラピュ―ティクスはイギリスのバイオ医薬品企業。臨床段階で、難病に対する治療薬の開発・商業化に取り組む。自己免疫の異常に起因するギラン・バレ―症候群に対するC5モノクロナ―ル抗体治療薬、また、発作性夜間ヘモグロビン尿症の治療薬の開発・商業化にも取り組む。同社パイプラインには「C5a」と「C5b-9」を含む。本社所在地は米国ニューヨーク。 Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom. |
| 本社所在地 | 75/76 Wimpole Street London 10018 GBR |
| 代表者氏名 | Ray Prudo レイプルード |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +44 20-8004-0261 |
| 設立年月日 | 38261 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 17人 |
| url | www.akaritx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aktx |
| adr_tso | 15208377 |
| EBITDA | EBITDA（百万ドル） -31.69758 |
| 終値（lastsale） | 2.05 |
| 時価総額（marketcap） | 31177172.85 |
| 時価総額 | 時価総額（百万ドル） 32.19213 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 17.12219 |
| 当期純利益 | 当期純利益（百万ドル） -31.85552 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Akari Therapeutics PLC (ADR) revenues was not reported. Net loss applicable to common stockholders decreased 27% to $9.4M. Lower net loss reflects Research and development costs decrease of 37% to $6.1M (expense) Changes in fair value of option and warr increase of 5% to $2.8M (income) Interest income increase of 71% to $132K (income). |
AKTXのテクニカル分析
AKTXのニュース
Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200-Day Moving Average of $1.88 2020/10/24 15:26:44 The Olympia Report
Akari Therapeutics PLC (NASDAQ:AKTX) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares changing hands. A number of equities analysts recently commented on AKTX […]
Akari Therapeutics (NASDAQ:AKTX) Share Price Crosses Below Two Hundred Day Moving Average of $1.88 2020/10/23 02:20:44 US Banking News
Akari Therapeutics PLC (NASDAQ:AKTX) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares traded. AKTX has been the topic of a number of recent analyst […]
Akari Therapeutics furthers clinal trials for Covid-19 pneumonia (NASDAQ:AKTX) 2020/10/06 15:30:00 Seeking Alpha
Akari Therapeutics (AKTX -1.6%) announces further progress in its COVID-19 pneumonia program with nomacopan in the U.S. and Brazil. Nomacopan’s dual comple
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia 2020/10/06 12:30:00 GlobeNewswire
FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior…
Biofarmacêutica deve testar possível tratamento para pneumonia ligada à covid no Brasil 2020/08/31 12:43:42 Valor Econômico
Nos Estados Unidos, uma etapa dos testes está em andamento Gerd Altmann/pixabay A biofarmacêutica inglesa Akari Therapeutics deve testar um possível tratamento para pneumonia relacionada à covid-19 no Brasil. Segundo a companhia, ensaios clínicos poderão ser realizados no país no quarto trimestre. Nos Estados Unidos, uma etapa dos testes está em andamento. No Reino Unido, o tratamento foi selecionado para um programa de ensaio clínico com cerca de 50 pacientes. Segundo a Akari, o tratamento age contra inflamações que provocam a pneumonia, o que poderá reduzir a mortalidade de pacientes com covid-19.
Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200-Day Moving Average of $1.88 2020/10/24 15:26:44 The Olympia Report
Akari Therapeutics PLC (NASDAQ:AKTX) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares changing hands. A number of equities analysts recently commented on AKTX […]
Akari Therapeutics (NASDAQ:AKTX) Share Price Crosses Below Two Hundred Day Moving Average of $1.88 2020/10/23 02:20:44 US Banking News
Akari Therapeutics PLC (NASDAQ:AKTX) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.88 and traded as low as $1.62. Akari Therapeutics shares last traded at $1.70, with a volume of 224,959 shares traded. AKTX has been the topic of a number of recent analyst […]
Akari Therapeutics furthers clinal trials for Covid-19 pneumonia (NASDAQ:AKTX) 2020/10/06 15:30:00 Seeking Alpha
Akari Therapeutics (AKTX -1.6%) announces further progress in its COVID-19 pneumonia program with nomacopan in the U.S. and Brazil. Nomacopan’s dual comple
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia 2020/10/06 12:30:00 GlobeNewswire
FDA clearance received to proceed with investigator-led multi-center double blind randomized clinical study in the U.S. with nomacopan following prior…
Biofarmacêutica deve testar possível tratamento para pneumonia ligada à covid no Brasil 2020/08/31 12:43:42 Valor Econômico
Nos Estados Unidos, uma etapa dos testes está em andamento Gerd Altmann/pixabay A biofarmacêutica inglesa Akari Therapeutics deve testar um possível tratamento para pneumonia relacionada à covid-19 no Brasil. Segundo a companhia, ensaios clínicos poderão ser realizados no país no quarto trimestre. Nos Estados Unidos, uma etapa dos testes está em andamento. No Reino Unido, o tratamento foi selecionado para um programa de ensaio clínico com cerca de 50 pacientes. Segundo a Akari, o tratamento age contra inflamações que provocam a pneumonia, o que poderá reduzir a mortalidade de pacientes com covid-19.
Biofarmacêutica deve testar possível tratamento para pneumonia ligada à covid no Brasil 2020/08/31 12:43:42 Valor Econômico
Nos Estados Unidos, uma etapa dos testes está em andamento Gerd Altmann/pixabay A biofarmacêutica inglesa Akari Therapeutics deve testar um possível tratamento para pneumonia relacionada à covid-19 no Brasil. Segundo a companhia, ensaios clínicos poderão ser realizados no país no quarto trimestre. Nos Estados Unidos, uma etapa dos testes está em andamento. No Reino Unido, o tratamento foi selecionado para um programa de ensaio clínico com cerca de 50 pacientes. Segundo a Akari, o tratamento age contra inflamações que provocam a pneumonia, o que poderá reduzir a mortalidade de pacientes com covid-19.
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings 2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment 2020/03/11 12:03:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Aytu Bioscience Inc (NASDAQ: AYTU ) ( announced a deal to distribute COVID-19 test) Centogene NV (NASDAQ: CNTG ) Forty Seven Inc (NASDAQ: FTSV ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 10) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) AngioDynamics, Inc. (NASDAQ: ANGO ) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Aptinyx Inc (NASDAQ: APTX ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Atossa Therapeutics Inc (NASDAQ: ATOS ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) AxoGen, Inc Common Stock (NASDAQ: AXGN ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Bausch Health Companies Inc (NYSE: BHC ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) BioLife Solutions Inc (NASDAQ: BLFS ) bluebird bio Inc (NASDAQ: BLUE ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Capricor Therapeutics Inc (NASDAQ: CAPR ) Celcuity Inc (NASDAQ: CELC ) Cerecor Inc (NASDAQ: CERC ) Chembio Diagnostics Inc (NASDAQ: CEMI ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Enochian Biosciences Inc (NASDAQ: ENOB ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evolus Inc (NASDAQ: EOLS ) Exicure Inc (NASDAQ: XCUR ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Gossamer Bio Inc (NASDAQ: GOSS ) Gritstone Oncology Inc (NASDAQ: GRTS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Heron Therapeutics Inc (NASDAQ: HRTX ) Incyte Corporation (NASDAQ: INCY ) INmune Bio Inc (NASDAQ: INMB ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Jaguar Health Inc (NASDAQ: JAGX ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kura Oncology Inc (NASDAQ: KURA ) Lantheus Holdings Inc (NASDAQ: LNTH ) TapImmune Inc.
Akari Therapeutics Announces Phase 3 Trial Design 2019/12/02 17:32:36 Investing News Network
The company has announced the design of its Phase 3 pediatric trial in HSCT-TMA after an end-of-Phase 2 meeting with the FDA. The post Akari Therapeutics Announces Phase 3 Trial Design appeared first on Investing News Network .
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting 2019/12/02 13:30:00 GlobeNewswire
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of…